Abstract:Schistosomiasis control is heavily reliant on the drug praziquantel (PZQ), which is used as preventive chemotherapy as part of national helminth control strategies. Given the heavy reliance on PZQ for mass drug administration, there has been considerable research on the potential of parasites developing resistance to the drug, resulting in decreased drug efficacy. However, there have been comparatively fewer studies of other factors that can potentially alter PZQ efficacy. Here, we investigate whether host PZQ metabolism contributes towards variable cure rates. We evaluate factors that can influence the metabolism of PZQ and the resultant effect on the efficacy of PZQ treatment to determine factors that potentially influence an individual's response to the drug. The literature search was directed at published studies from three online databases: Web of Science, PubMed, and EMBASE. The search terms for the review comprised of ([praziquantel OR PZQ] AND [schistosom* OR bilharzia] AND [pharmaco*]) and included studies evaluating PZQ metabolism. Publications were categorised into pharmacokinetics, drug–drug interactions, pharmacogenetics, and metabolite analysis. Forty publications describing human and experimental studies fitted the inclusion criteria and were subjected to data extraction and analysis. The analyses showed that variable exposure to PZQ was associated with alterations in the liver's capacity to metabolise PZQ and observed drug–drug interactions. Other factors influencing the efficacy of PZQ were brand, formulation, and co-administered food. Although some work has been performed on metabolite identification, there was minimal information on PZQ's metabolic pathway, and no pharmacogenetics studies were identified. The study indicated that in both human and experimental studies alterations in the liver's capacity to metabolise PZQ as well as drug–drug interactions affected systemic levels of PZQ that could result in variable cure rates. The study confirmed previous findings of higher antischistosomal activity of (R)-PZQ enantiomer when administered alone compared to the racemate at the same dose as well as improved efficacy when the drug is administered with food. The study also highlighted the need for more comprehensive studies of the PZQ metabolic pathway and PZQ pharmacogenetic studies in humans.Schistosomiasis is a neglected tropical disease caused by parasitic worms, and its control is heavily reliant on the drug praziquantel (PZQ). Reports of individuals not being cured of schistosomiasis after a treatment have raised concerns about drug efficacy and the potential for the development of drug resistance. Many factors can be responsible for reduced efficacy including host, parasite, and drug–related factors. We investigated the potential effect of varying systemic levels of PZQ on cure rates. We reviewed studies on PZQ metabolism identifying factors that may influence PZQ systemic levels, including the drug administered, host liver health, and genetic polymorphisms of liver enzymes involved in PZQ metabolism. The results indicated that varying levels of PZQ were due to the drug formulation and differences in the liver's capacity to metabolise PZQ as well as drug–drug interactions. The study also highlighted the need for further studies of the effect of human genetics on PZQ's metabolic pathway, and the PZQ metabolites produced.

Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models

Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection

How improvements to drug effectiveness impact mass drug administration for control and elimination of schistosomiasis

In vivo praziquantel efficacy of Schistosoma japonicum over time: A systematic review and meta-analysis

CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

Extensive transmission and variation in a functional receptor for praziquantel resistance in endemic

Treatment of acute schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice. Maintenance of resistance to infection

Extensive transmission and variation in a functional receptor for praziquantel resistance in endemic Schistosoma mansoni

Efficacy and safety of prazequantel for the treatment of Schistosoma mansoni infection across different transmission settings in Amhara Regional State, northwest Ethiopia

Praziquantel and factor H recruitment differentially affect the susceptibility of Schistosoma mansoni to complement-mediated damage

Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda

Factors affecting the uptake of preventive chemotherapy treatment for schistosomiasis in Sub-Saharan Africa: A systematic review

Efficacy of Praziquantel in Treating Schistosoma haematobium Infection Among Ethiopian Children

Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis

New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel

Considering ivermectin for treatment of schistosomiasis

Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale

Transcriptional phenotype of the anti-parasitic benzodiazepine meclonazepam on the blood fluke Schistosoma mansoni

Pharmacokinetics of praziquantel and its metabolites in grass carp (Ctenopharyngodon idella) following the oral administration of a single bolus

Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings